Failure of acyclovir cream in treatment of recurrent herpes labialis. 1985

M Shaw, and M King, and J M Best, and J E Banatvala, and J R Gibson, and M R Klaber

A double blind, randomised, crossover placebo controlled trial of 5% acyclovir cream, applied topically five times a day for five days, was carried out in 45 patients with recurrent herpes labialis. These patients had a total of 72 episodes, 34 of which were treated with the 5% acyclovir cream and 38 with placebo cream. Treatment was begun by the patients as soon as possible after the onset of prodromal symptoms. There was no significant clinical benefit from treatment with acyclovir cream compared with placebo cream. The median healing times were nine days with acyclovir cream, 10 days with placebo cream, and 13 days when no treatment was given. The possibility that the 40% propylene glycol cream base alone has a therapeutic effect must therefore be considered.

UI MeSH Term Description Entries
D008297 Male Males
D011409 Propylene Glycols Derivatives of propylene glycol (1,2-propanediol). They are used as humectants and solvents in pharmaceutical preparations. Propanediols,Glycols, Propylene
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D006560 Herpes Labialis Herpes simplex, caused by type 1 virus, primarily spread by oral secretions and usually occurring as a concomitant of fever. It may also develop in the absence of fever or prior illness. It commonly involves the facial region, especially the lips and the nares. (Dorland, 27th ed.) Cold Sore,Fever Blister,Herpes Simplex, Labial,Blister, Fever,Blisters, Fever,Cold Sores,Fever Blisters,Labial Herpes Simplex,Sore, Cold,Sores, Cold
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000212 Acyclovir A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes. Acycloguanosine,9-((2-Hydroxyethoxy)methyl)guanine,Aci-Sanorania,Acic,Aciclobeta,Aciclostad,Aciclovir,Aciclovir Alonga,Aciclovir-Sanorania,Acifur,Acipen Solutab,Acivir,Activir,Acyclo-V,Acyclovir Sodium,Antiherpes Creme,Avirax,Cicloferon,Clonorax,Cusiviral,Genvir,Herpetad,Herpofug,Herpotern,Herpoviric,Isavir,Laciken,Mapox,Maynar,Milavir,Opthavir,Supraviran,Viclovir,Vipral,Virax-Puren,Virherpes,Virmen,Virolex,Virupos,Virzin,Wellcome-248U,Zoliparin,Zovirax,Zyclir,aciclovir von ct,Aci Sanorania,Aciclovir Sanorania,Acyclo V,Alonga, Aciclovir,Sodium, Acyclovir,Solutab, Acipen,Virax Puren,ViraxPuren,Wellcome 248U,Wellcome248U

Related Publications

M Shaw, and M King, and J M Best, and J E Banatvala, and J R Gibson, and M R Klaber
July 1985, British medical journal (Clinical research ed.),
M Shaw, and M King, and J M Best, and J E Banatvala, and J R Gibson, and M R Klaber
September 1985, British medical journal (Clinical research ed.),
M Shaw, and M King, and J M Best, and J E Banatvala, and J R Gibson, and M R Klaber
January 1996, BMJ (Clinical research ed.),
M Shaw, and M King, and J M Best, and J E Banatvala, and J R Gibson, and M R Klaber
February 1990, The Journal of infectious diseases,
M Shaw, and M King, and J M Best, and J E Banatvala, and J R Gibson, and M R Klaber
June 2008, Medizinische Monatsschrift fur Pharmazeuten,
M Shaw, and M King, and J M Best, and J E Banatvala, and J R Gibson, and M R Klaber
April 1996, BMJ (Clinical research ed.),
M Shaw, and M King, and J M Best, and J E Banatvala, and J R Gibson, and M R Klaber
January 1987, Acta stomatologica Croatica,
M Shaw, and M King, and J M Best, and J E Banatvala, and J R Gibson, and M R Klaber
November 2000, The Medical letter on drugs and therapeutics,
M Shaw, and M King, and J M Best, and J E Banatvala, and J R Gibson, and M R Klaber
January 2000, Acta dermato-venereologica,
M Shaw, and M King, and J M Best, and J E Banatvala, and J R Gibson, and M R Klaber
September 1983, The British journal of dermatology,
Copied contents to your clipboard!